Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients (POSOVIR)
Taking antiretrovirals once-a-day is considered the simpler way to improve adherence. However, it is not know if this assertion apply to patients taking their medication twice-a-day who change to once-a-day.
We hypothesized that once-daily dosing improves adherence.
Behavioral: Nevirapine from twice-a-day to once-a-day
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
- MEMS adherence by electronic devices [ Time Frame: 28-week period (randomized phase) ]
- Virologic efficacy (RNA HIV<400cp/ml)
- Immunologic efficacy (CD4 count cells)
- Tolerance (hepatic, cutaneous, ANRS safety grade scale)
- Pharmacokinetics (nevirapine dosages)
|Study Start Date:||June 2004|
|Study Completion Date:||November 2006|